Stockscreener 앱 받기
0.1703
5.25%
0.0085
시간 외 거래:
.17
-0.0003
-0.18%
전일 마감가:
$0.1618
열려 있는:
$0.1599
하루 거래량:
1.02M
Relative Volume:
1.41
시가총액:
$6.79M
수익:
$94,000
순이익/손실:
$-13.28M
주가수익비율:
-0.0233
EPS:
-7.2965
순현금흐름:
$-11.67M
1주 성능:
-5.18%
1개월 성능:
-20.27%
6개월 성능:
-68.79%
1년 성능:
-93.57%
1일 변동 폭
$0.1599
$0.1756
1주일 범위
$0.1599
$0.183
52주 변동 폭
$0.1599
$2.8771
AIM ImmunoTech Inc Stock (AIM) Company Profile
명칭
AIM ImmunoTech Inc
전화
352 448 7797
주소
2117 SW Highway 484, Ocala, FL
Compare AIM vs VRTX, MRNA, REGN, ARGX, ONC
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
AIM
AIM ImmunoTech Inc
|
0.1703 | 6.79M | 94,000 | -13.28M | -11.67M | -7.2965 |
VRTX
Vertex Pharmaceuticals Inc
|
508.75 | 128.95B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
236.50 | 94.42B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
796.34 | 81.99B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
846.27 | 53.22B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
374.08 | 42.32B | 5.76B | 514.49M | 1.10B | 4.4813 |
AIM ImmunoTech Inc 주식(AIM)의 최신 뉴스
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Highlights Recent Media Coverage of - GlobeNewswire
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
57 patients with stable pancreatic cancer received an immune-modulating drug after chemotherapy. - Stock Titan
AIM ImmunoTech Spotlights Growing Attention Around - GlobeNewswire
AIM ImmunoTech Discusses Ampligen®’s Potential to - GlobeNewswire
AIM ImmunoTech Announces Virtual 2026 Annual Stockholders Meeting and Proxy Details - Kalkine Media
AIM ImmunoTech Submits 2025 Annual Report Highlighting Focus on Ampligen for Pancreatic Cancer - Kalkine Media
AIM ImmunoTech Discusses Ampligen®’s Potential to Complement Emerging Pancreatic Cancer Therapies in New CEO Corner Video - The Manila Times
A 39-patient exploratory analysis reported 34.8 months’ median survival in pancreatic cancer. - Stock Titan
AIM ImmunoTech Highlights Ampligen’s Potential Role in the Evolving Pancreatic Cancer Treatment Landscape Following FDA Approval of Revolution Medicines’ Daraxonrasib - markets.businessinsider.com
AIM Looks 71.3% Undervalued on GF Value™ Despite Financial Strug - GuruFocus
AIM ImmunoTech Highlights Ampligen’s Potential Role in the - globenewswire.com
AIM ImmunoTech Inc Share PriceAIM, RNS News, Articles, Quotes, & Charts (AMEX:AIM) - Proactive financial news
Aim Immunotech Stock Price Forecast. Should You Buy AIM? - StockInvest.us
Aim ImmunoTech CEO Equels buys $4,992 in stock - Investing.com
Aim ImmunoTech CEO & president buys $2,310 in company stock - Investing.com
Aim ImmunoTech CEO & President Thomas Equels buys $4,862 in stock - Investing.com
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - The Globe and Mail
AIM ImmunoTech Reduces Debt via Equity Exchange Agreements - TipRanks
AIM ImmunoTech Converts ~$450,000 of Note Into 1.92M Shares in Exchanges With Streeterville - TradingView
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive - GlobeNewswire
AIM ImmunoTech Highlights Scientific Rationale, Supportive Data and Continued Advancement of Ampligen® in Pancreatic Cancer in New CEO Corner Video - Yahoo Finance
AIM ImmunoTech Eliminates $1.22 Million Debt via Stock Exchange - minichart.com.sg
AIM ImmunoTech Extinguishes Debt Through Equity Exchanges - TipRanks
AIM ImmunoTech Secures Ampligen Patent Protection in Europe - Intellectia AI
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global - GlobeNewswire
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - The Manila Times
AIM ImmunoTech Secures European and U.K. Patent Protection for Ampligen in Long COVID Through 2041 - Quiver Quantitative
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - Yahoo Finance
AIM ImmunoTech Significantly Expands Ampligen® Global Patent Estate with Long COVID Protection Across Europe and the United Kingdom Through 2041 - GlobeNewswire
AIM ImmunoTech Extends IP Protection for Ampligen Through 2039 with Broad US Patent - Contract Pharma
AIM Looks 69.6% Undervalued on GF Value™ Despite Financial Distr - GuruFocus
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod (Ampligen®) Used in Combination with Pembrolizumab (Keytruda®), Expanding Oncology IP Protection for Ampligen Through 2039 - The Manila Times
AIM ImmunoTech Secures U.S. Patent for Ampligen Combination with Pembrolizumab in Cancer Treatment - Quiver Quantitative
AIM ImmunoTech Secures Broad U.S. Patent for Rintatolimod - GlobeNewswire
AIM patent covers Ampligen with Keytruda across cancers through 2039 - Stock Titan
AIM Q2 2026 Earnings: Wider Than-Expected Loss as Clinical-Stage Costs PersistProfit Inflection Point - vinanet.vn
AIM ImmunoTech Inc. (AIM) Shareholding Pattern – Promoters, FIIs & DIIs - Value Research
AIM ImmunoTech Inc. (AIM) Key Financial Ratios – Valuation, Profitability & More - Value Research
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - manilatimes.net
AIM ImmunoTech doses final patient in pancreatic cancer trial - stocktitan.net
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - Yahoo Finance
AIM ImmunoTech Participates in the Virtual Investor 'Why Now' On-Demand Conference - Moomoo
AIM ImmunoTech Participates in the Virtual Investor ‘Why Now’ On-Demand Conference - GlobeNewswire
AIM | AIM ImmunoTech Inc. FinancialsRevenue Breakdown - quiverquant.com
AIM ImmunoTech (AIM) Stock Forecast & Analyst Ratings - Moomoo
AIM Maintained by Ascendiant Capital -- Price Target Lowered to $7.00 - GuruFocus
AIM ImmunoTech Inc (AIM) 재무 분석
매출
순이익
현금흐름
주당 순 이익
AIM ImmunoTech Inc 주식 (AIM) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Equels Thomas K | CEO & President |
Sep 16 '26 |
Buy |
0.21 |
11,000 |
2,310 |
102,822 |
| Equels Thomas K | CEO & President |
Sep 15 '26 |
Buy |
0.22 |
22,000 |
4,862 |
91,822 |
| Equels Thomas K | CEO & President |
Sep 14 '26 |
Buy |
0.22 |
5,900 |
1,292 |
69,822 |
1.35%
자본화:
|
볼륨(24시간):